ANTITHROMBOTIC AGENTS

• US 20070190059A1
• Filed: 01/12/2007
• Published: 08/16/2007
• Est. Priority Date: 01/17/1996
• Status: Abandoned Application

• Current Assignee: University of Vermont & State Agricultural College
• Original Assignee: Smithkline Beecham Corporation (GSK plc)
• Inventors: Blackburn, Michael, Feuerstein, Giora, Barone, Frank, Toomey, John
• Application Number:
  US11/622,623
• Publication Number:
  US 20070190059A1
• Time in Patent Office: Days
• US Class Current: 424/146.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/36 against blood coagulation factors
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Monoclonal antibodies directed against coagulation factor IX and their use in inhibiting thrombosis are disclosed.

Claims

1. A method for treating an animal post-thromboembolic induced ischemia comprising administering an anti-Factor IX antibody or antibody fragment.

2. The method of claim 1 wherein the anti-Factor IX antibody or antibody fragment is administered post-embolus.

3. The method of claim 1 wherein the anti-Factor IX antibody or antibody fragment is administered post-stroke.

4. The method of claim 1 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 249417, SB 257731 or SB 257732.

5. The method of claim 4 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249417.

6. A method for treating an animal post-thromboembolic induced ischemia comprising administering SB 249417.

7. A method for treating an animal post-thromboembolic induced ischemia comprising administering an anti-Factor IX antibody or antibody fragment in combination with a plasminogen activator.

8. The method of claim 7 wherein the anti-Factor IX antibody or antibody fragment and plasminogen activator are administered post-embolus.

9. The method of claim 7 wherein the anti-Factor IX antibody or antibody fragment and plasminogen activator are administered post-stroke.

10. The method of claim 7 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 249417, SB 257731 or SB 257732.

11. The method of claim 10 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249417.

12. The method of claim 7 wherein the thrombolytic agent is tPA, urokinase, streptokinase or variants thereof.

13. The method of claim 12 wherein the thrombolytic agent is tPA.

14. A method for treating an animal post-thromboembolic induced ischemia comprising administering SB 249417 in combination with tPA.

15. A method for reducing a required dose of a thrombolytic agent in treatment of an animal post-thromboembolic induced ischemia comprising administering an anti-Factor IX antibody or antibody fragment in combination with the thrombolytic agent.

16. The method of claim 15 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 249417, SB 257731 or SB 257732.

17. The method of claim 16 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249417.

18. The method of claim 15 wherein the thrombolytic agent is tPA, urokinase, streptokinase or variants thereof.

19. The method of claim 18 wherein the thrombolytic agent is tPA.

20. A method for preventing thromboembolic stroke in an animal comprising administering an anti-Factor IX antibody or antibody fragment to an animal at risk for thromboembolic stroke.

21. The method of claim 20 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 249417, SB 257731 or SB 257732.

22. The method of claim 20 wherein the anti-Factor IX antibody or antibody fragment has the identifying characteristics of SB 249417.

23. A method of preventing thromboembolic stroke in an animal comprising administering SB 249417 to an animal at risk for thromboembolic stroke.